SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with 203Pb-PSC-panitumumab in NRG mice
Panitumumab was successfully and reproducibly labelled with <sup>203</sup>Pb in high radiochemical purity using the chelator PSC-NCS. <sup>203</sup>Pb-PSC-panitumumab was specifically accumulated and retained in EGFR + tumours in NRG mice with s.c. HNSCC PDX. <sup>203</sup>Pb-PSC-panitumumab is a suitable immuno-SPECT radioligand for imaging EGFR + tumours and has great potential for combining with <sup>212</sup>Pb-PSC-panitumumab in a radiotheranostic strategy for imaging and treating HNSCC.
Authors
- Afsaneh Lavasanifar (ORCID: https://orcid.org/0000-0001-5108-7124)
- Raymond M. Reilly (ORCID: https://orcid.org/0000-0003-1038-7993)
- Michael K. Schultz (ORCID: https://orcid.org/0000-0002-4554-2212)
- Nasim Sarrami
- Jalna Meens (ORCID: https://orcid.org/0000-0001-5274-3744)
- Samantha Leier
- Melinda Wuest (ORCID: https://orcid.org/0000-0003-0735-2749)
- John S. Wilson
- Teesha Komal
- Conrad Chan
- Bryce J. B. Nelson (ORCID: https://orcid.org/0000-0003-3735-303X)
- Laurie Ailles (ORCID: https://orcid.org/0000-0001-7289-8882)
- Frank Wuest (ORCID: https://orcid.org/0000-0002-6705-6450)
Institutions
- University Health Network (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Viewpoint Molecular Targeting (United States) (US)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s41181-024-00313-8
- Citations
- 2
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.81